Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Defense Tech ETF (SHLD) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Global X Defense Tech ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Global X Defense Tech ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Defense Tech ETF trades at $59.88 (market cap $6.29B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.7× Global X Defense Tech ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and Zimmer Biomet Holdings Inc for 89 Days on average.

SHLDZBH
Market Cap
$6.29B$16.95B
Volume
1,133,2522,505,240
Sector
Sector/ThematicHealth
52-Week High
$78.02$103.98
52-Week Low
$58.20$79.58
Typical Hold Time
44 Days89 Days
Enterprise Value
—$24.02B
Dividend Yield
—1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Defense Tech ETF

SHLD, the Global X Defense Tech ETF, trades at $58.74, down 2.2% on the day amid a bearish technical signal. The ETF focuses on defense technology and cybersecurity, with recent institutional buying interest noted in filings. However, key financial ratios like P/E and P/S are not available for this ETF, and the overall technical picture is negative, with moving averages and oscillators signaling bearish momentum.

The outlook for SHLD is mixed, with potential tailwinds from rising global defense spending and institutional accumulation, but weighed down by bearish technicals and the absence of clear valuation metrics. Risks include geopolitical shifts and ETF-specific performance versus peers. The investment case hinges on sustained defense budget growth and SHLD's ability to capture tech-driven defense innovation.

Zimmer Biomet Holdings Inc

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SHLD
100% Buy0% Sell
Avg holding period · 44 Days
ZBH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Global X Defense Tech ETF

SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.

Read more on SHLD →

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH →